News Release

一种“无细胞”疗法可令心脏组织再生且没有细胞移植风险

Peer-Reviewed Publication

American Association for the Advancement of Science (AAAS)

A "Cell-Less" Therapy May Regenerate Heart Tissue Without Cell Transplant Risks (1 of 2)

image: An exosome derived from heart cells grown from human induced pluripotent stem cells. This material relates to a paper that appeared in the Sep. 16, 2020, issue of Science Translational Medicine, published by AAAS. The paper, by L. Gao at University of Alabama at Birmingham in Birmingham, AL; and colleagues was titled, "Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine." view more 

Credit: L. Gao <i>et al., Science Translational Medicine</i> (2020)

Ling Gao和同事研发出了一种利用外泌体(即由细胞分泌的微小的与膜结合的液囊)的策略,它能模仿心脏细胞移植的心脏再生作用,但可同时避免与完整细胞移植有关的风险。他们的方法(在猪体内加速了心肌梗塞后的恢复)或可解决安全性和有效性问题,这些问题阻止了临床对完整细胞心脏疗法的采用。近年来,研究人员探索了用诱导多能干细胞生长的心脏细胞移植物来愈合(在诸如心肌梗塞等事件后)心脏组织的可能性 。但是,移植的心脏细胞通常无法被植入接受者的体内,它们会在植入几天后消亡。临床医生还担心,真的被植入的细胞可能会导致如心律失常等严重健康问题,甚或最终促成肿瘤的形成。与其移植完整细胞。 Gao等人通过仅给予外泌体(即细胞分泌的含有蛋白和DNA的微小容器)来解决这些问题。具体而言,他们从3种人类心脏细胞(即平滑肌细胞、心肌细胞和内皮细胞)中分离出外泌体,并将其注入心肌梗塞后的猪心。与未经治疗的猪相比,接受了外泌体的猪的心功能恢复得更好,显示的疤痕更小,其情况改善堪比接受完整细胞移植的猪。Gao等人说,脱细胞外泌体“可令医生充分利用hiPSC衍生细胞的心脏保护和修复特性,并同时避免与细胞存储、运输和免疫排斥等有关的复杂问题。”

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.